Selvedge Venture

Founders Alasdair Thong and Robert Thong run the firm. The website lists them as the two principals; titles beyond 'Founder' are not published, and no separate CIO or investment committee is disclosed.

Selvedge Venture invests exclusively into companies targeting the three age-related medical conditions that account for the largest share of global healthcare spend and mortality: metabolic syndrome (including cardiovascular disease, diabetes, fatty liver disease, and obesity), cancer, and neurodegenerative diseases. Every position must sit at the confluence of biotechnology and digital/machine-learning tooling.

The firm invests from Pre-Seed through Series A, with a commitment to founders and start-ups whose science is ready for scaling. No later-stage or growth-equity activity is mentioned in its public materials.

Publicly referenced positions span cell therapy manufacturing (Kytopen, which raised a $30 million Series A), glucose-responsive insulin technology via Carbometrics' collaboration with Novo Nordisk and the University of Bristol (published in Nature), AI-driven clinical triage, transdermal drug delivery, computational systems biology, and a chemistry platform. The firm groups its companies under descriptors rather than publishing a full portfolio list.

No. The firm's own site states it is 'not for retail clients' and is intended solely for professional investors under MiFID II definitions, accompanied by an explicit risk warning that capital invested is high-risk and may be entirely lost.

Public disclosures describe only direct early-stage equity investments into operating companies. No fund-of-funds activity, SPV structures, or co-investment clubs are mentioned on the firm's website or in available public records.

Selvedge Venture is headquartered in London. Its portfolio extends to innovation clusters in the United Kingdom and Cambridge, Massachusetts, the latter linked to a cell therapy manufacturing spinout from an MIT lab. No additional office locations are listed.